Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tabelecleucel - Atara Biotherapeutics

Drug Profile

Tabelecleucel - Atara Biotherapeutics

Alternative Names: Allogeneic Epstein Barrr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; ATA-129; EBV targeted T-cell therapy - Atara/MSKCC; EBV-CTL - Atara/MSKCC; EBV-specific T-cells - Atara/MSKCC; Ebvallo; EbvalloTM; Epstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center; Tab-cel®

Latest Information Update: 25 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Lymphoproliferative disorders
  • Phase I/II Nasopharyngeal cancer

Most Recent Events

  • 20 Dec 2023 Atara Biotherapeutics completes Commercialisation agreement with Pierre Fabre for USA
  • 29 Nov 2023 Pooled adverse events and efficacy data from three phase II trials and an expanded-access protocol in indication) released by PureTech Health
  • 19 Sep 2023 Atara Biotherapeutics announces intention to submit BLA to the US FDA for Lymphoproliferative disorder in Q2 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top